July 17, 2017 09:09 AM EDTUpdated May 26, 08:50 PM

FDA embraces the first US application for a gene therapy, offering an accelerated test case

Spark Therapeutics $ONCE is getting a short cut at the FDA for its lead gene therapy program, winning a priority review and a January …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA em­braces the first US ap­pli­ca­tion for a gene ther­a­py, of­fer­ing an ac­cel­er­at­ed test case